NLRP3 and cryopyrin-associated periodic syndrome: As the role of the NLRP3 inflammasome pathway has been thoroughly studied in autoinflammatory conditions, in this review we will touch upon relevant features of the NLRP3 inflammasome activation process, discuss the clinical features of CAPS and the role of NLRP3 dysfunction in this latter, review the efficacy of therapies for CAPS, describe potential novel therapeutic targets whereby clinical trials are ongoing and briefly discuss some of the newly emerging molecules targeting NLRP3 inflammasome which have been assessed in CAPS mouse models.